Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Todd Asset Management LLC

Todd Asset Management LLC decreased its position in Bristol-Myers Squibb (NYSE:BMY) by 3.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 540,945 shares of the biopharmaceutical company’s stock after selling 18,325 shares during the quarter. Todd Asset Management LLC’s holdings in Bristol-Myers Squibb were worth $27,756,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. OFI Invest Asset Management acquired a new stake in Bristol-Myers Squibb during the third quarter worth approximately $25,000. Milestone Investment Advisors LLC purchased a new stake in shares of Bristol-Myers Squibb in the third quarter valued at $27,000. Blue Bell Private Wealth Management LLC increased its stake in Bristol-Myers Squibb by 61.5% in the third quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 200 shares during the last quarter. Legacy Financial Group LLC purchased a new position in Bristol-Myers Squibb during the third quarter worth about $39,000. Finally, Turtle Creek Wealth Advisors LLC acquired a new stake in Bristol-Myers Squibb in the 4th quarter worth about $40,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently commented on BMY. StockNews.com lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday, April 15th. BMO Capital Markets cut their target price on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research report on Friday, April 26th. Barclays lowered their price target on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research report on Friday, April 26th. Societe Generale downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Finally, William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $60.00.

Bristol-Myers Squibb Stock Up 0.7 %

Shares of NYSE BMY traded up $0.29 during midday trading on Friday, reaching $43.99. 12,104,489 shares of the company’s stock were exchanged, compared to its average volume of 14,314,010. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. Bristol-Myers Squibb has a 52-week low of $43.33 and a 52-week high of $69.10. The business’s fifty day moving average price is $50.37 and its two-hundred day moving average price is $50.74. The stock has a market capitalization of $89.17 billion, a PE ratio of -14.19, a price-to-earnings-growth ratio of 14.82 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.53) by $0.13. The company had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. Bristol-Myers Squibb’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same period in the previous year, the business earned $2.05 EPS. Analysts forecast that Bristol-Myers Squibb will post 0.59 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 5.46%. The ex-dividend date was Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is currently -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.